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 Envenoming resulting from snake bites is an important public health hazard in many regions, particularly in tropical and subtropical countries [1–3]. Although 
antivenoms are being produced by various laboratories in 
every continent, the burden of snake bite envenoming—
causing both morbidity and mortality—still has a great impact 
on the population and on health-care systems, especially in 
Africa, Asia, Oceania, and Latin America [4]. Unfortunately, 
public health authorities, nationally and internationally, have 
given little attention to this problem, relegating snake bite 
envenoming to the category of a major neglected disease of 
the 21st century.
 The Global Burden of Snake Bite Envenoming
 In the tropical developing countries where snake bites occur 
most commonly, there are few reliable incidence data. One 
serious attempt to assess global snake bite mortality was the 
survey undertaken by Swaroop and Grabb in 1954, which was 
based largely on hospital admissions [3]. Subsequent work 
has revealed gross underreporting of deaths in this study—for 
example, in Nigeria [5] and Thailand [1,6]. One reason 
is that records of patients treated by traditional methods 
are missing from ofﬁ cial databased statistics, and deaths 
reported at the hamlet or district level may not be sent on 
to ministry headquarters. Accepting these limitations, the 
fragmentary evidence available suggests that several million 
bites and envenomings occur worldwide each year, with tens 
of thousands of deaths [2,3].
 Properly designed population surveys are likely to give a 
far more accurate picture of snake bite incidence, morbidity, 
and mortality. In Asia, the highest recorded mortality was 
162 snake bite deaths per 100,000 people per year, in the 
Eastern Terai of Nepal [7]. In Africa, for instance, the 
incidence of snake bites in the Benue Valley of northeastern 
Nigeria was 497 per 100,000 people per year, with a mortality 
of 12.2% [5]. The reasons for the high levels of snake bite 
mortality in tropical developing countries include scarcity 
of antivenoms, poor health services, and difﬁ culties with 
rapid access to health centres [8]. Large numbers of victims 
survive with permanent physical and psychological sequelae, 
mostly due to the tissue-damaging effects of snake venoms. 
Young agricultural workers, especially males, are the most 
highly affected group, making snake bite envenoming a truly 
occupational disease—a fact that is frequently overlooked by 
national authorities. Children are also common victims of 
snake bites. There is signiﬁ cant seasonal variation in snake 
bite incidence that is attributable to climate, especially to 
rain fall and temperature, which determine annual cycles of 
agricultural activity.
 Species That Cause High Morbidity and Mortality
 Most severe cases of snake bite envenoming are inﬂ icted 
by species of the family Elapidae (cobras, kraits, mambas, 
Australasian species, and sea snakes) and the family Viperidae 
(rattlesnakes, lance-headed pit vipers, and true vipers). The 
species causing the largest numbers of bites and fatalities are 
 Echis sp. (saw-scaled vipers) in northern Africa,  Bothrops asper 
and  B. atrox (lance-headed pit vipers) in Central and South 
America, and  Naja sp. (cobras) and  Bungarus sp. (kraits) in 
Asia [6, 9–11] (Figure 1). Many other species, although not 
responsible for a large number of cases worldwide, constitute 
a serious problem in speciﬁ c regions.
 Clinical Features of Snake Bite Envenoming
 Envenomings by most viperid snakes inﬂ ict prominent 
local tissue damage, characterised by swelling, blistering, 
haemorrhage, and necrosis of skeletal muscle (Figure 2). 
Bites by some elapids, such as African spitting cobras and 
some Asian cobras, also induce local necrosis. Such local 
pathology is mostly due to the action of phospholipases A2 
and zinc-dependent metalloproteinases [12,13]. These local 
effects develop rapidly after the bite; consequently, a delay 
in the access to health facilities frequently results in drastic 
tissue damage and permanent disability. Systemic effects 
of envenoming are also common and more immediately 
life-threatening. In elapid snake bites, neurotoxicity 
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is a typical consequence, attributable to effects of pre- 
and/or postsynaptically acting neurotoxins targeting 
neuromuscular junctions. These toxins cause progressive 
descending paralysis, which may become life-threatening 
when bulbar and respiratory muscles are involved. In 
envenomings by several elapid snakes and some viperids, 
such as South American rattlesnakes, there is a generalised 
rhabdomyolysis induced by phospholipases A2, which may 
cause myoglobinaemia, hyperkalaemia, and acute renal 
failure. Systemic effects in viperid snake bites include 
spontaneous haemorrhage—cerebral haemorrhage being the 
most serious manifestation—deﬁ brinogenation, disseminated 
intravascular coagulation, and cardiovascular shock secondary 
to hypovolaemia, vasodilation, and direct effects on the 
myocardium. Acute renal failure and acute respiratory 
distress syndrome are also described following viperid 
snake bites. There are abundant exceptions to this general 
pathophysiological proﬁ le since the amazing complexity 
of snake venom proteomes includes toxins with diverse 
clinical effects (see [14] for a general view on the clinical 
manifestations of snake bite envenomings).
 Antivenoms and Ancillary Treatments in Envenoming
 The intravenous administration of animal-derived (mostly 
horse or sheep) antivenoms is the mainstay and the 
only speciﬁ c treatment of snake bite envenoming. Many 
laboratories produce antivenoms using various methodologies, 
which yield three different types of products depending on 
the nature of the active principle. In some cases, antivenoms 
consist of whole IgG molecules, but the majority of producers 
manufacture antivenoms composed of F(ab′)2 fragments 
obtained by pepsin digestion of IgG, and a few laboratories 
produce Fab fragments after papain digestion of IgG [4,15]. 
Variations in the molecular mass of the active principle, as 
well as other immunological divergences among these types 
of antivenoms, determine different pharmacokinetic proﬁ les, 
with evident pharmacodynamic implications—such as the 
described recurrence of envenoming—especially when using 
Fab antivenoms [16]. The large immunochemical diversity 
of snake venoms explains why the efﬁ cacy of antivenoms is 
generally restricted to a limited geographical and biological 
spectrum.
 Clinical investigations have established that generally 
antivenoms are highly effective in the neutralisation of 
toxins responsible for systemic effects such as haemorrhage, 
coagulopathy, and haemodynamic disturbances. Similarly, 
a rapid reversal of neurotoxicity caused by postsynaptic 
neurotoxins in elapid envenomings is well established 
[1]. In contrast, antivenoms are not very effective in the 
reversal of neurotoxicity induced by presynaptically acting 
phospholipases A2. The main problem associated with 
antivenom efﬁ cacy has to do with local tissue damage [1]. 
This problem is not due to the lack of neutralizing antibodies 
in antivenoms, but rather to the extremely rapid development 
of local pathology, which renders it difﬁ cult for neutralizing 
antibodies to access the area before irreversible damage 
occurs [17]. 
 Antivenom safety is also of current concern since, 
although the safety proﬁ le of some products is satisfactory, 
the administration of other antivenoms is associated with 
a high incidence of early and late adverse reactions [4,15]. 
The precise mechanisms responsible for these reactions 
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 Figure 1.  Snakes Causing High Incidence of Envenomings in Africa, 
Asia, and Latin America
 (A)  Echis ocellatus (saw-scaled viper, family Viperidae, from Nigeria), 
(B)  Naja naja (cobra, family Elapidae, from Sri Lanka), and (C)  B. asper 
(terciopelo or equis, family Viperidae, from Costa Rica) are responsible for 
many snake bite envenomings in sub-Saharan Africa, Asia, and Central 
America, respectively. Envenomings by  E. ocellatus and  B. asper , as well 
as by related viperid species, induce prominent local tissue damage 
that often results in permanent sequelae and disability, and systemic 
alterations associated with haemorrhage, coagulopathy, cardiovascular 
shock, and renal failure. Envenomings by  N. naja and other Asiatic cobras 
induce systemic neurotoxic effects and local necrosis. 
 (Image: D. A. Warrell [A and B]; Mahmood Sasa [C]) 
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have not been clearly established, although there is strong 
evidence pointing to direct complement activation, effects 
of contaminating pyrogens, and reactions to immune 
complexes. The physicochemical characteristics of 
antivenoms—principally, the presence of protein aggregates, 
the purity of the active principle, and the total dose of 
protein administered—seem to be the main determinants 
of reactogenicity. Early adverse reactions are treated with 
adrenaline, antihistamines, or corticosteroids [6,9].
 Besides antivenom administration, the therapy of snake bite 
envenoming involves a number of ancillary interventions [6]. 
Assisted ventilation is life saving when the respiratory muscles 
are affected, and administration of acetylcholinesterase 
inhibitors has been used with success in some neurotoxic 
envenomings [6]. Hypovolaemia in viperid envenoming is 
corrected by the administration of plasma expanders, and 
dialysis or haemoperfusion may be needed in cases of acute 
renal failure. Renal damage by myoglobin or haemoglobin 
released by rhabdomyolysis or intravascular haemolysis may 
be prevented by rehydration and alkalinisation. Tetanus 
prophylaxis should be routine, and antibiotics may be 
required if signs of local infection develop. The bitten limb 
may require surgical debridement of necrotic tissue, but 
fasciotomy is rarely justiﬁ ed.
 Developing New Treatments to Reduce Local Tissue 
Damage
 Hydrolases such as metalloproteinases, phospholipases 
A2, and possibly hyaluronidases are mostly responsible for 
the local tissue damage frequently observed in snake bite 
envenoming. It is very difﬁ cult for IgG and its fragments to 
neutralise these toxins, so there is an urgent need to develop 
new therapies to counteract local venom effects. Venom 
hydrolases are homologous with endogenous mammalian 
enzymes, such as matrix metalloproteinases, a disintegrin 
and metalloproteinase (ADAM) enzymes, and inﬂ ammatory 
phospholipases A2. The pharmaceutical industry has 
developed a large number of inhibitors to these mammalian 
enzymes because of their relevance in many pathologies. 
Since many of these drugs have already been tested in 
clinical trials, there is an excellent opportunity to use some 
of these inhibitors to prevent local effects of snake bite 
envenoming. For instance, the peptidomimetic hydroxamate 
metalloproteinase inhibitor “batimastat” is highly effective 
in preventing local tissue damage and some systemic 
effects induced by the venom of  B. asper  [18,19]. Similarly, 
phospholipase A2 and hyaluronidase inhibitors have proven 
successful at reducing the extent of venom-induced tissue 
damage at the experimental level [20,21]. The advantages of 
this strategy are the following: (1) such inhibitors are usually 
low-molecular-mass components that can diffuse rapidly 
in the tissues, and (2) such inhibitors would be effective 
against a wide variety of venom metalloproteinases and 
phospholipases A2 present in the venoms of different genera 
and species, since most of them act at the active sites of these 
enzymes, which are highly conserved.
 Towards More Effective and Safer Antivenoms
 Despite the success of antivenoms in the therapy of snake bite 
envenoming, a number of research groups are working to 
improve the quality of antivenoms using different approaches: 
(1) new immunisation strategies, such as DNA immunisation 
or the use of puriﬁ ed relevant toxins as antigens instead of 
the whole venom [22]; (2) improved methods of antibody 
puriﬁ cation, aiming to obtain more reﬁ ned products with 
reduced protein content [23]; (3) improved viral safety of 
antivenoms, by introducing steps such as pasteurisation, 
caprylic acid stabilisation, and nanoﬁ ltration [24]; (4) the 
search for other animal species from which it is possible to 
derive antivenoms—such as camels, which have a particular 
type of IgG devoid of light chains, and hens, which have IgY 
in their egg yolk [25]; and (5) preparation of antivenoms 
that combine complete antibodies with recombinant 
“nanobodies”, which by having a very low molecular mass 
may reach tissue compartments more readily than whole IgG 
or conventional IgG fragments [26]. In addition, there is a 
clear need for the design and development of controlled, 
randomised clinical trials in many countries to assess the 
effectiveness and safety of the antivenoms being used or 
introduced in such regions.
 Conclusion: The Need for a Global Partnership
 In various parts of the world, there is a continuing crisis in 
the production, deployment, and accessibility of antivenoms. 
This is particularly serious in Africa since various traditional 
suppliers have stopped producing antivenoms for this 
continent, and the privatisation of other producers has also 
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 Figure 2.  Extensive Tissue Necrosis of the Lower Limb in an 11-Year-
Old Boy Who Had Been Bitten Two Weeks Earlier by a  B. asper in 
Ecuador
 Only antibiotic treatment had been given, so tissue damage was 
extensive, requiring above-knee amputation. Such pathological 
alterations are caused by the direct action of locally acting toxins in the 
venom (mostly metalloproteinases and phospholipases A
2
), together 
with an indirect effect promoted by local inﬂ ammatory events and 
ischemia secondary to venom-induced vascular damage and increased 
intracompartmental pressure. 
 (Image: D. A. Warrell) 
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affected supply. It is therefore a matter of great urgency to 
promote international collaboration—best coordinated by 
the World Health Organization—involving national and 
regional health organisations and diverse public–private 
partnerships in order to accomplish the following goals: 
(1) to gather accurate epidemiological information on the 
impact and characteristics of snake bite envenoming in 
many regions, using properly designed community studies; 
and (2) to provide effective and safe antivenoms in those 
regions where they are not currently available. This includes, 
in the short term, the commitment of various laboratories 
to produce antivenoms for these regions, such as the efforts 
being undertaken by various producers to manufacture new 
antivenoms for use in Africa [27–29]. Innovative approaches 
to pharmaceutical laboratories, both public and private, 
should be initiated in order to foster improvement in 
antivenom supply [30,31]. The long-term goal should be 
to generate an effective transfer of antivenom-producing 
technologies to regions hyperendemic for snake bites, to 
allow them to manufacture their own antivenoms (Figure 3). 
 Besides the technological issues of antivenom 
production and supply, efforts should be devoted in Africa, 
Asia, Oceania, and Latin America to the preparation of 
consensus guidelines and protocols for treatment and 
prevention of snake bites [32], and to the establishment 
of teaching programmes in medical and nursing schools. 
There is a need to develop health intervention strategies, 
adapted for the particular needs of every country and 
region, to achieve more rapid access to antivenom in health 
facilities. Such integrated and global efforts, involving many 
participants, will undoubtedly reduce the global burden of 
human suffering inﬂ icted by this neglected disease. 
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 Figure 3.  Scientiﬁ c, Technological, and Political Tasks Required to Improve the Prevention and Treatment of Snake Bite Envenoming
 There is an urgent need to gain a deeper knowledge of the epidemiology and clinical manifestations of snake bite envenoming around the globe, 
and to promote research and public health policies aimed at improving the treatment and prevention of these envenomings, particularly regarding 
antivenom production and distribution, as well as training of medical staff. The fulﬁ lment of these tasks requires a concerted effort involving many 
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